Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-acting injectable cabotegravir for the prevention of HIV infection
Meredith E. Clement, Ryan Kofron, Raphael J. Landovitz
Current Opinion in HIV and AIDS (2019) Vol. 15, Iss. 1, pp. 19-26
Open Access | Times Cited: 93

Showing 26-50 of 93 citing articles:

Interactive effects of morphine and the HIV integrase inhibitor, cabotegravir, in male and female mice
Candy Carbajal, Florida Owens, Natalie L. Stone, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 184, pp. 117925-117925
Open Access
PrEP Navigator Perceptions of the Implementation of Injectable PrEP on HIV Prevention in Tennessee
Cristian J. Chandler, David G. Schlundt, Chloe Dagostino, et al.
International Journal of Environmental Research and Public Health (2025) Vol. 22, Iss. 5, pp. 662-662
Open Access
Perceptions of Long-Acting Injectable Antiretroviral Therapy Among People Living with HIV Who Use Drugs and Service Providers: a Qualitative Analysis in Rhode Island
Alexandra B. Collins, E. Claire Macon, Kirsten J. Langdon, et al.
Journal of Urban Health (2023) Vol. 100, Iss. 5, pp. 1062-1073
Closed Access | Times Cited: 9
Design and synthesis of fluorine aromatic scaffolds containing drugs approved by the US FDA from 2002 to 2022
Pengfei Xu, Lijun Zhu, Desheng Zhang, et al.
Results in Chemistry (2024) Vol. 7, pp. 101446-101446
Open Access | Times Cited: 3
Current status of the small molecule anti-HIV drugs in the pipeline or recently approved
T. Umumararungu, Jean Baptiste Nyandwi, Jonathan Katandula, et al.
Bioorganic & Medicinal Chemistry (2024) Vol. 111, pp. 117860-117860
Closed Access | Times Cited: 3
A new engineering process of biodegradable polymeric solid implants for ultra-long-acting drug delivery
Panita Maturavongsadit, Gayane Paravyan, Martina Kovářová, et al.
International Journal of Pharmaceutics X (2020) Vol. 3, pp. 100068-100068
Open Access | Times Cited: 22
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model
Lucile Pencolé, Minh Patrick Lê, Florian Bouchet-Crivat, et al.
AIDS (2020) Vol. 34, Iss. 14, pp. 2145-2149
Open Access | Times Cited: 19
Identification of Determinants and Implementation Strategies to Increase Long-Acting Injectable PrEP for HIV Prevention Among Latino Men Who Have Sex with Men (MSM)
Juan Pablo Zapata, Alithia Zamantakis, Artur Acelino Francisco Luz Nunes Queiroz
Journal of Racial and Ethnic Health Disparities (2023) Vol. 11, Iss. 4, pp. 2093-2102
Closed Access | Times Cited: 7
A mini-review on integrase inhibitors: The cornerstone of next-generation HIV treatment
Fathi Shalbi, Ahmed R. Ali
European Journal of Medicinal Chemistry (2024) Vol. 279, pp. 116900-116900
Closed Access | Times Cited: 2
Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery
Duy‐Khiet Ho, Clare L. M. LeGuyader, Selvi Srinivasan, et al.
Journal of Controlled Release (2020) Vol. 329, pp. 257-269
Open Access | Times Cited: 17
Knowledge of HIV and HIV pre-exposure prophylaxis among medical and pharmacy students: A national, multi-site, cross-sectional study
Samuel R. Bunting, Brian A. Feinstein, Aniruddha Hazra, et al.
Preventive Medicine Reports (2021) Vol. 24, pp. 101590-101590
Open Access | Times Cited: 16
The role of machine learning in HIV risk prediction
Joshua Fieggen, Eli Smith, Lovkesh Arora, et al.
Frontiers in Reproductive Health (2022) Vol. 4
Open Access | Times Cited: 11
Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates
Fernanda P. Pons‐Faudoa, Antons Sizovs, Kathryn A. Shelton, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 16
Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women
Andrew T. Gustin, Ross Cromarty, Luca Schifanella, et al.
Seminars in Immunology (2021) Vol. 51, pp. 101482-101482
Open Access | Times Cited: 13
Safety and Pharmacokinetic Profiles of Long-Acting Injectable Antiretroviral Drugs for HIV-1 Pre-Exposure Prophylaxis: A Systematic Review and Meta-analysis of Randomized Trials
L Gilbert, Vincent Kharisma Wangsaputra, Christianto, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 13
Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis
Spencer H. Durham, Ashlee N. Milam, Dylan Waer, et al.
Annals of Pharmacotherapy (2022) Vol. 57, Iss. 3, pp. 306-316
Closed Access | Times Cited: 9
Testing the Effectiveness of a Motivational Interviewing Intervention to Reduce HIV Risk and Drug Use in Young Sexual Minority Men in a Community-Based Organization Setting
Tyrel J. Starks, Steven Samrock, David López, et al.
AIDS and Behavior (2023) Vol. 28, Iss. 1, pp. 26-42
Closed Access | Times Cited: 5
Long-acting implantable devices for the prevention and personalised treatment of infectious, inflammatory and chronic diseases
Francesca Corduas, Elena Mancuso, Dimitrios A. Lamprou
Journal of Drug Delivery Science and Technology (2020) Vol. 60, pp. 101952-101952
Open Access | Times Cited: 14
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP)
Carolina Herrera, Julianne Lwanga, Ming Lee, et al.
Journal of Antimicrobial Chemotherapy (2021) Vol. 76, Iss. 8, pp. 2129-2136
Open Access | Times Cited: 11
High Rates of Pre-exposure Prophylaxis Eligibility and Associated HIV Incidence in a Population With a Generalized HIV Epidemic in Rakai, Uganda
Victor Ssempijja, Gertrude Nakigozi, Robert Ssekubugu, et al.
JAIDS Journal of Acquired Immune Deficiency Syndromes (2022) Vol. 90, Iss. 3, pp. 291-299
Open Access | Times Cited: 8
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis
Hannah A. Blair
Drugs (2022) Vol. 82, Iss. 14, pp. 1489-1498
Closed Access | Times Cited: 8
Pre-exposure prophylaxis service among men who have sex with men in Malaysia: findings from a discrete choice experiment
Alex Dubov, Frederick L. Altice, José I. Gutierrez, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 4
In VitroExposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles
Emily Bowman, Cheryl Cameron, Brian Richardson, et al.
Antimicrobial Agents and Chemotherapy (2020) Vol. 65, Iss. 1
Open Access | Times Cited: 11
Adolescent-Centered HIV Prevention: Perspectives on Acceptability of Oral Antiretroviral Pre-exposure Prophylaxis for Adolescents in a Global Priority Setting
Danielle Giovenco, Caroline Y. Kuo, Kristen Underhill, et al.
Archives of Sexual Behavior (2021) Vol. 50, Iss. 7, pp. 2921-2931
Open Access | Times Cited: 10
Estimating benefits of using on-demand oral prep by MSM: a comparative modeling study of the US and Thailand
Sarah Stansfield, Mia Moore, Marie‐Claude Boily, et al.
EClinicalMedicine (2022) Vol. 56, pp. 101776-101776
Open Access | Times Cited: 7

Scroll to top